AstraZeneca plc (ADR) (AZN) reported quarterly earnings results on Thursday, Jul-28-2016. The company reported $0.83 EPS for the quarter. Analysts had a consensus estimate of $0.83. The company posted revenue of $5603.00 million in the period, compared to analysts expectations of $5596.35 million. The company’s revenue was down -4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.21 EPS.
Many Wall Street Analysts have commented on AstraZeneca plc (ADR). AstraZeneca plc (ADR) was Initiated by Argus to “Hold” on Jul 12, 2016.
AstraZeneca plc (ADR) opened for trading at $32.54 and hit $34.35 on the upside on Thursday, eventually ending the session at $34.29, with a gain of 8.72% or 2.75 points. The heightened volatility saw the trading volume jump to 1,99,65,134 shares. Company has a market cap of $86,754 M.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).